Accera
Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.
Pioneering breakthroughs in neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment.
Accera, established in 2001 and based in Broomfield, Colorado, is a pioneering biotechnology firm in the fields of neurodegenerative therapies for Alzheimer’s, Parkinson’s, and age-related memory impairment. The company is focused on the discovery and development of therapeutic drugs aimed at neurodegenerative diseases. Their flagship innovation, Ketasyn, is a molecule intended to address conditions such as Alzheimer's, Parkinson's, and age-related memory impairment. Accera recently received a significant $50.00M in a Venture Round investment on 04 October 2018, with Inventages and Wilmar International as the participating investors. The company’s dedication to addressing critical unmet medical needs in the neurodegenerative space has attracted notable support from leading investors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $50.00M | 2 |
|
04 Oct 2018 |
| Venture Round | $17.64M | - | 26 Mar 2018 | |
| Private Equity Round | $69.08M | - | 25 Oct 2013 | |
| Series D | $11.00M | 3 |
|
03 Jan 2011 |
| Series C | $35.00M | 2 |
|
12 Nov 2008 |
No recent news or press coverage available for Accera.
We care about your data, and we'd love to use cookies make your experience better.
